Biomarker & Intervention Discovery
Sjögren's Syndrome
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionChronic and progressive; glandular dysfunction (dry eyes/mouth) irreversible in most; fatigue and systemic features…
Best-intervention remissionHydroxychloroquine: limited systemic benefit; rituximab: parotid gland improvement and fatigue in some trials but…
Gap sizeVery large — no approved disease-modifying therapy; symptomatic management only for glandular features
Primary barrierbiological + access
Full remission profile →
Remission & chronicity
Spontaneous remission
Chronic and progressive; glandular dysfunction (dry eyes/mouth) irreversible in most; fatigue and systemic features fluctuate; lymphoma risk 5-15x general population; spontaneous full remission rare
Best-intervention remission
Hydroxychloroquine: limited systemic benefit; rituximab: parotid gland improvement and fatigue in some trials but primary endpoint failure in Phase 3 (TEARS, TRACTISS); no disease-modifying therapy approved; best outcomes with early systematic sicca management
Gap size
Very large — no approved disease-modifying therapy; symptomatic management only for glandular features
Primary barrier
biological + access
Sjögren's research has been hampered by heterogeneous disease and lack of validated endpoints; rituximab failed multiple Phase 3 trials despite positive Phase 2 data (endpoint selection problem); anti-Ro/SSA positivity enriches trials but treatment effects still modest; diagnosis itself is delayed 4-7 years on average
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Sjögren's Syndrome” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."